FEDERAL COURT OF AUSTRALIA
Arrow Pharmaceuticals Limited v Merck & Co., Inc. [2005] FCA 188
ARROW PHARMACEUTICALS LIMITED v MERCK & CO., INC.
NSD 1211 OF 2002GYLES J
9 MARCH 2005
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD 1211 OF 2002
BETWEEN:
ARROW PHARMACEUTICALS LIMITED
APPLICANTAND:
MERCK & CO., INC.
RESPONDENTJUDGE:
GYLES J
DATE OF ORDER:
9 MARCH 2005
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1 Subject to order 2 the respondent pay the applicant’s costs of the proceedings.
2 The applicant pay the respondent’s costs:
(a)arising out of service of the affidavits of John Anthony Eden, Thomas John Martin, Michael Jeffrey Hooper and Martin Epstein and the provision of related patient records;
(b)of and incidental to the issues raised by paragraphs 8, 9, 10 and 11 of the Fourth Further Amended Particulars of Invalidity.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD 1211 OF 2002
BETWEEN:
ARROW PHARMACEUTICALS LIMITED
APPLICANTAND:
MERCK & CO., INC.
RESPONDENT
JUDGE:
GYLES J
DATE:
9 MARCH 2005
PLACE:
SYDNEY
REASONS FOR JUDGMENT
Orders were made in this matter on 8 October last. Those orders followed the delivery of reasons on 6 October 2004 (Arrow Pharmaceuticals Limited v Merck & Co., Inc. [2004] FCA 1282). The issue of costs was stood over for further argument. In the course of the reasons for judgment I said:
‘As to costs, my present view is that Merck should pay Arrow’s costs of the proceeding, excluding costs relating to particulars of invalidity on the ground of novelty which were not pursued at trial.’
Broadly speaking, the applicant is content with that result. The respondent argues for apportionment of costs between particular issues.
The parties have proposed competing orders for costs which are respectively:
The applicant:
‘The Respondent pay the Applicant’s costs of the proceedings, excluding costs relating solely to particulars of invalidity on the ground of novelty which were:
(a)not pursued at trial; and
(b)
not relevant to the validity of claims of the Patent which were abandoned by the Respondent in making the amendments referred to in:
(i) order 1 of the orders of 8 October 2004; or
(ii) the orders of 25 February 2004
Such costs are to be taxed if not agreed by the parties.’
The respondent:
‘(a)The Respondent pay the Applicant’s costs of the issues finally determined against the Respondent in these proceedings or relating solely to the validity of claims of the Patent which were abandoned by the Respondent in making the amendments referred to in order 1 of the orders of 8 October 2004.
(b)The Applicant pay the Respondent’s costs of the issues finally determined against the Applicant in these proceedings or relating solely to the issues raised by the Applicant but not pursued at trial.
(c)Costs of the issues not yet decided by the…
Keep reading for free
Create a free CaseChat account to read Arrow Pharmaceuticals Limited v Merck and Co., Inc. and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2005] FCA 188
- Decision Date
CaseChat Overview and Summary
The central legal issues that the court had to address were whether the patents in question met the criteria for patentability and if Arrow had sufficiently demonstrated that these patents were invalid. This involved a detailed analysis of the patents' claims, the prior art, and the extent to which the patents met the statutory requirements for novelty, inventive step, and utility. The court also had to consider the evidence presented by both parties, including expert testimonies and documentary evidence, to make a determination on the validity of the patents.
In its judgment, the court found that Arrow had not provided sufficient evidence to invalidate the patents in question. The court concluded that the patents met the requirements of novelty and inventive step, and were sufficiently disclosed in the patent applications. The court also found that the claims of utility were adequately supported by the evidence provided. Consequently, the court dismissed Arrow's application for revocation of the patents. The court also ordered that Arrow pay the costs associated with the proceedings, subject to certain exceptions, and that Merck be reimbursed for specific costs related to the service of affidavits and provision of patient records.
Orders
Orders of the court
1 Subject to order 2 the respondent pay the applicant’s costs of the proceedings.
2 The applicant pay the respondent’s costs:
(a) arising out of service of the affidavits of John Anthony Eden, Thomas John Martin, Michael Jeffrey Hooper and Martin Epstein and the provision of related patient records;
(b) of and incidental to the issues raised by paragraphs 8, 9, 10 and 11 of the Fourth Further Amended Particulars of Invalidity.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: GYLES J
Full text does not contain this section.